Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 257

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 3
Chunk 257
---
15/24$1.5510/28/2202/15/23$1.4809/06/2411/15/24$1.5509/08/2311/15/23$1.4809/09/2211/15/22$1.4106/21/2408/15/24$1.5506/22/2308/15/23$1.4806/23/2208/15/22$1.4102/15/2405/15/24$1.5502/16/2305/15/23$1.4802/17/2205/16/22$1.41Stock Repurchase ProgramThe company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management’s discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses and are available for general corporate purposes. On February 16, 2023, AbbVie's board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 7 million shares for $1.3 billion in 2024, 10 million shares for $1.6 billion in 2023 and 8 million shares for $1.1 billion in 2022. AbbVie's remaining stock repurchase authorization was $3.5 billion as of December 31, 2024. 

2024 Form 10-K   |  90

Accumulated Other Comprehensive LossThe following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2024, 2023 and 2022:(in millions) (brackets denote losses)Foreign currency translation adjustmentsNet investment hedging activitiesPension and post-employment benefitsCash flow hedging activitiesTotalBalance as of December 31, 2021$(570)$(91)$(2,546)$308 $(2,899)Other comprehensive income (loss) before reclassifications(943)629 915 91 692 Net losses (gains) reclassified from accumulated other comprehensive loss— (74)173 (91)8 Net current-period other comprehensive income (loss)(943)555 1,088 — 700 Balance as